Patients with Ewing sarcoma family of tumors (ESFT) who are resistant even to salvage chemotherapy, have dismal prognoses and few therapeutic options. Because the docetaxel/irinotecan (DI) combination has not been previously evaluated in ESFT, we prospectively evaluated its use in patients with recurrent or refractory ESFT.
Yoon et al BMC Cancer 2014, 14:622 http://www.biomedcentral.com/1471-2407/14/622 RESEARCH ARTICLE Open Access A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors Jong Hyung Yoon1, Mi Mi Kwon1, Hyeon Jin Park1, Seog Yun Park1,2, Kun Young Lim3, Jungnam Joo4 and Byung-Kiu Park1* Abstract Background: Patients with Ewing sarcoma family of tumors (ESFT) who are resistant even to salvage chemotherapy, have dismal prognoses and few therapeutic options Because the docetaxel/irinotecan (DI) combination has not been previously evaluated in ESFT, we prospectively evaluated its use in patients with recurrent or refractory ESFT Methods: Patients aged